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Objective: The predefined duration to arbitrarily stop the tests during constant-load treadmill exercise is a subject of
debate and widely variable in the literature. We hypothesized that the upper and lower limits for predefined durations of
constant-load 3.2 km/hour 10% grade tests could be derived from the distribution of walking distances observed on a
treadmill in a population of subjects referred for claudication or from the optimal cutoff point distance on a treadmill to
confirm a limitation self-reported by history.
Methods:We conducted a retrospective analysis using a referral center, institutional practice, and ambulatory patients. We
studied 1290 patients (86% male), 62.1  11.2 years of age, 169  8 cm height, 75.7  14.2 kg weight. Patients
performed a standard constant-load treadmill test: 3.2 km hour1, 10% slope, maximized to 1000 meters (20minutes).
We analyzed the maximal walking distance self-reported (MWDSR) by history and the maximal walking distance
measured on the treadmill (MWDTT). Patients reporting MWDSR >1000 meters were considered unlimited by history.
Results: Only 197 patients (15.3%) completed the 20-minute treadmill test. Among the 504 patients who did not stop
before 250 meters, 47.8% stopped within the next 250 meters (were unable to walk 500 meters). This proportion falls to
7.5% among the 213 patients who did not stop before 750 meters. When the final goal was to estimate whether the
treadmill test can discriminate patients with or without limitation by history, area under the receiver operating
characteristic (ROC) curve was 0.809  0.016 (95% confidence interval [CI], 0.778-0.841; P < .0001), the best
diagnostic performance was attained for an MWDTT of 299 meters (6.15 minutes).
Conclusion: In patients undergoing constant-load treadmill exercise with a protocol of 3.2 km hour1 and 10% slope: a
predefined duration of 7 minutes could be proposed as a lower limit for the predefined duration of the tests specifically
if one aims at confirming the limitation by history with treadmill testing. Owing to the low risk that patients that could
walk 750 meters (15 minutes) will have to stop in the next 250 meters, 15 minutes seems a reasonable upper limit for
the predefined test duration in clinical routine. (J Vasc Surg 2010;51:863-8.)Treadmill diagnostic tests are used in patients with
peripheral artery disease (PAD) to try to reproduce symp-
toms reported by history and argue for their arterial origin,
or to objectively estimate maximal walking distance (the
distance at which claudication forces the patient to stop
exercise). Constant-load exercise is largely used since this
procedure is expected to better reproduce usual walking
rather than incremental exercise. In constant-load treadmill
tests, there is a direct linear relationship between the dis-
tance performed and duration of the test. The predefined
duration to stop the tests during constant-load treadmill
exercise is generally defined arbitrarily but remains widely
variable in the literature and is a subject of debate.1-7
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doi:10.1016/j.jvs.2009.11.044Estimation of walking capacity by the patient’s inter-
view is readily accessible, whereas treadmill testing is not
accessible to most physicians. Further, a person’s function-
ality and need for daily walking distances may be less than
that tested on a treadmill, questioning the need of a tread-
mill test to assess walking ability. Last, as many treadmill
tests are performed with a slope, a climb on a treadmill at a
steady pace is not a natural walking scenario, and this
particular test cannot be expected to correspond exactly to
the walking that patients do in their everyday life. There-
fore, many physicians take patients’ reports of their every-
day experience at the reference value. If the self-reported
walking capacity is taken as a reference, then what is the
distance on a treadmill that better predicts self-reported
distance? The objective determination of this cutoff tread-
mill distance could be proposed to calculate the lower limit
for the predefined duration to be used for these treadmill
tests. Indeed, if the predefined duration is too short, there
is a risk of misclassification of the patients.
Maximal distance walked on a treadmill is suggested in
guidelines as the gold-standard in the evaluation of walking
capacity in patients with PAD.8 Whatever the speed and
slope used, it is likely that if the treadmill test duration
chosen is too short, patients completing the test may be
declared “unlimited” from the result of the treadmill test,
whereas they would have had to stop for claudication if the
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patients will theoretically reach a limit (at least due to
fatigue) if exercise duration is extended infinitely, but when
the probability that the patient will stop if the test duration
is extended becomes too low, it is useless and costly to
increase the test duration. Indeed, when walking on a
treadmill at a constant load, patients (eg, patients who
usually walk fast) may remain asymptomatic or may show
nonlimiting claudication and be able to carry on walking
despite the occurrence of claudication. We hypothesized
that the distribution of distances walked by patients re-
ferred for claudication could provide useful information
toward the reasonable upper limit for the predefined dura-
tion that should be used for constant-load treadmill tests.
In perspective of which gold-standard is used, we aimed
to objectively determine the lower and upper limit that
could be proposed for predefined test duration (the dura-
tion at which the test is ended) when one aims at determin-
ing walking capacity during constant-load 3.2 km/hour
10% slope treadmill diagnostic testing in patients with
claudication of suspected arterial origin.
MATERIALS AND METHODS
Study population. A retrospective analysis of data
from all new patients referred to our laboratory for tread-
mill exercise walking tests between 2001 and 2009 was
performed. These tests are used in our department for
patients with claudication to have an objective measure-
ment of walking capacity, specifically for patients who are
referred for eventual surgery or re-education. Many pa-
tients are also referred for claudication of suspected arterial
origin, atypical (proximal) claudication, or claudication of
questionable vascular origin (eg, association of PAD with
lumbar spine syndrome). Asymptomatic patients (eg, pa-
tients undergoing systematic screening) were excluded
from the study. Patients who had multiple tests during the
study period (eg, to control the treatment’s efficacy) were
included only for their first visit. The study was submitted
to the ethics committee and conforms to Helsinki Declara-
tion but, as an observational noninterventional study, is not
registered in a web-accessible database, and does not re-
quire patient’s consent.
Walking capacity by history. Before the treadmill
test, patients were asked to estimate their walking capacity
through the self-reported maximal walking distance (MWDSR)
by answering the question “What is the maximal distance
that you think you may attain all-at-once at usual pace and
on a flat area before limb pain or discomfort forces you to
stop walking?”
Walking capacity on treadmill. Patients who were
able to walk 10 meters in 12 seconds in the corridor before
the treadmill test were proposed a standard treadmill test
under cardiac monitoring as previously described.9 Patients
unable to walk the 10meters in 12 seconds were considered
unable to perform the standard treadmill tests, were pro-
posed a specific low-speed protocol, and were excluded
from the present study. The standard test uses a 10% slope,
at a speed of 3.2 km/hour. The 3.2 km/hour speed wasreached within 1 minute to allow for the patient’s adapta-
tion to treadmill walking. Before the tests, patients were
instructed to report all symptoms (limiting and nonlimit-
ing) occurring during the test (claudication and other than
claudication). They were also informed that the test could
be stopped on their request at any time when their symp-
toms forced them to stop (and not when claudication first
occurs). In the absence of symptoms or in case of nonlim-
iting symptoms, we fixed the maximum duration of tread-
mill exercise to 20 minutes (1000 meters). For all tests,
we recorded the maximal walking distance performed on
treadmill by the patient (MWDTT).
Analysis of the results and statistical analysis. To
avoid confusion, throughout the manuscript the pre-
defined test limit is expressed as time (minutes) and self-
reported or treadmill-measuredmaximal capacity (MWDSR
and MWDTT) are reported as distances (meters). The
receiver operating characteristics (ROC) curve analysis
was performed on raw data of MWDTT. Distribution of
MWDTT among all patients and among the patients who
did not complete the test, respectively, was tested for
normality with the Z for Kolmogorov-Smirnov test on raw
data and log-transformed data to test for a normal and
log-normal distribution, respectively. For the histogram
representation of its distribution, MWDTT were grouped
by intervals of 50 meters, starting with “less than 50
meters” to “1000 meters or more” (1000 or ). Walking
limitation by history was defined as an MWDSR 1000
meters because we previously showed that MWD at a usual
pace is on average 2 to 3 times higher than that walking on
a treadmill in PAD patients.10 Comparison between groups
was performed with a 2 test for categoric variables and
Mann-Whitney test or unpaired t test for continuous vari-
ables pending normal distribution. Last, we used the ROC
curve to analyze the diagnostic accuracy of treadmill test-
ing, and define the optimal cutoff point for MWDTT to
confirm walking limitation by history. On ROC curves, the
distance (arbitrary units) to the 100/100% sensitivity/
specificity angle can be calculated for each point of the
curve (each possible cutoff point). The lowest value of this
distance represents the optimal cutoff point for clinical use
assuming an equal cost of false positive and false negative
results. Statistical analyses were performed with SPSS v
15.0. For all tests, a two-tailed P .05 was used to indicate
statistical significance.
RESULTS
Population studied. Patients included were 1109
males and 181 females. Characteristics of included patients
by gender are presented in Table I. All patients reported
exercise-related proximal (n  324; 21.1%), distal (n 
598; 46.4%) or proximodistal (n  368; 28.5%) unilateral
or bilateral claudication. Of the 1290 patients, 304 (23.6%)
previously had surgery and/or angioplasty at the aortoiliac
and or femorodistal level. It is of interest to note that 91
patients (7.1%) had undergone negative investigations to-
ward, or were symptomatic after surgery of, lumbar spine
syndrome.
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were unable to precise their treatment that was not available
in the patient’s files. Of all patients, 926 (71.8%) received
antiplatelet drugs or anticoagulants, 581 (45.0%) received
cholesterol-lowering agents, 586 (45.4%) received antihy-
pertensive drugs,* and 245 (19.0%) received beta blockers.
Last, on the average, patients were symptomatic for
more than 2 years (range, 0.25-23 years) when referred to
the laboratory, mean  SD being 2.1  2.9 years in
females, and 2.4  3.1 years in males.
Maximal walking distance by history. Before exer-
cise, limitation by history to less than 250 meters was
reported by 563 patients (43.6%), limitation by history
from 250 to less than 500 meters was reported by 223
patients (17.3%), from 500 to less than 750 meters by 224
patients (17.4%), and from 750 to less than 1000 meters by
24 patients (1.9%). No limitation or limitation in excess of
1000 meters was reported by history by 256 patients
(19.8%).
Maximal walking distance on treadmill. The distri-
bution of distance walked during the 1290 tests is pre-
sented in the Fig. The distribution of all data values neither
fits to a normal or log-normal distribution (Z 8.028, P
.0001 and Z  3.742, P  .0001, respectively). Among
these completed tests, 61 tests were performed with the
patient remaining asymptomatic throughout the tests, 6
patients reported nonlimiting dyspnea or fatigue, whereas
nonlimiting claudication was reported during the other
130 tests. In 1093 patients (84.7%), the treadmill was
stopped before 1000 meters. Reason for exercise stop was:
claudication only (n  828), claudication associated with
*Antihypertensive include: sartans, converting enzyme inhibitors, calcium
Table I. Characteristics of the patients studied. Results ar
Characteristics
Age (years)
Height (cm) 1
Weight (kg)
Body mass index (kg/m2)
Vascular results
ABI (units)a
Abnormal vascular investigationsb
Reported history of vascular surgery
Aortoiliac/femorodistal
Cardiac/other peripheral vascular beds
Reported comorbid conditions
History of cancer
Arthritis/arthroplasty
Pulmonary disease/diabetes
Lumbar spine syndrome excluded/operated
Diabetes
Active smokersc
ABI, Ankle brachial index.
aData for ABI was available in 130 females and 872 patients.
bAbnormal vascular investigation means either ABI0.9; ABI1.3, presen
DROP value 15 mm Hg.
cData for smoking was available in 132 females and 808 males.channel blockers, alpha blockers, and diuretics.non-lower limb symptoms (n 207), and non-limb symp-
tom without claudication (n  58). When the distribution
of MWDTT was analyzed only among the 1093 patients
who could not complete the test, results were Z  4.667
(P  .0001) on raw data and Z  0.721 (P  .676) on
log-transformedMWDTT. Then the distribution of MWDTT
among patients who could not complete the treadmill test
follows a log-normal distribution.
As shown, 197 of the 1290 patients (15.3%) completed
the 20-minute treadmill test. In brief, for the whole popu-
lation, 241 of 504 patients (47.8%) who did not stop within
Fig. Maximal walking distance observed on treadmill (MWDTT)
stratified by intervals of 50 meters. The numbers in bold indicate
the total number of patients by intervals of 250 meters.
orted as mean  SD or as numbers (percentages)
ales Males P values
 14.0 61.9  10.7 .12
 6.0 170.6  6.6 .01
 12.7 77.8  13.4 .01
 4.8 26.7  4.2 .01
 0.24 0.77  0.25 .82
55.2) 848 (76.5) .51
7.7) 243/64 (27.7) .01
8.3) 109/52 (14.5) .03
1.1) 29 (2.6) .30
6.6) 56 (5.0) .28
1.7) 33 (3.0) .46
3.3) 75/10 (7.7) .05
15.5) 198 (17.9) .46
22.1) 267 (24.1) .64
50% stenosis at ultrasound scan or radiologic imaging, or exercise tcpO2e rep
Fem
63.3
58.0
63.2
25.3
0.77
134 (
8/6 (
8/7 (
2 (
12 (
3 (
6/0 (
28 (
40 (
ce of athe first 250 meters, stopped within the next 250 meters
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patients (19.0%) and 16 of 213 patients (7.5%) of those that
did not stop before 500 meters and before 750 meters,
respectively, stopped within the next 250meters of the test.
Maximal walking distance on a treadmill to predict
maximal walking distance by history. Table II shows the
diagnostic performance of treadmill in predicting limitation
defined by history. As expected, 966 of the 1034 patients
(93.4%) reporting limitation by history did not complete
the 20-minute (1000 meter) treadmill test. Nevertheless,
127 of the 256 patients (49.6%) reporting unlimited walk-
ing capacity by history had to stop the treadmill test and
were unable to walk 1000 meters on a treadmill (between
group 2  301; P  .0001).
Area under the ROC curve was 0.809  0.016 (95%
confidence interval [CI], 0.778-0.841; P  .0001) for
treadmill distance to predict exercise limitation defined by
history. The best diagnostic performance of MWDTT to
discriminate patients with or without walking limitation
was attained for aMWDTT of 299meters (6.15minutes).
DISCUSSION
The major original findings of this study can be sum-
marized as follows. When using a standard treadmill
constant-load test at 3.2 km/hour and 10% slope in pa-
tients tested for claudication suspected of vascular origin:
(1) the distribution of distance walked on treadmill is a
log-normal distribution among subjects who could not
complete the full 1000 meters. The probability that the
patient who walked 750 meters will stop in the next 250
meters is lower than 10%; (2) if one aims at confirming a
self-reported walking capacity of less than 1000meters with
a treadmill test (MWDSR as a gold-standard) the optimal
cutoff MWDTT issued from the ROC curve analysis is 299
meters.
Constant-load treadmill exercise. There is a debate
about which technique is preferable to test patients with
Table II. Diagnostic performance observed for different
cutoff point values of MWDTT, when the goal is to use
treadmill results to predict self-reported limitation vs
no limitation
Gold standard used for MWDSR (meters) MWDSR 1000
Cutoff limit used for MWDTT (meters) 250 500 750 1000
True negative (n) 195 147 134 129
False positive (n) 61 109 122 127
False negative (n) 309 116 79 68
True positive (n) 725 918 955 966
Sensitivity (%) 70 89 92 93
Specificity (%) 76 57 52 50
Positive predictive value (%) 92 89 89 88
Negative predictive value (%) 39 56 63 65
MWDSR, Maximal walking distance self-reported; MWDTT, maximal walk-
ing distance on a treadmill.
Results are presented for self-reported limitation defined as a maximal
walking distance of less than 1000 meters.claudication on a treadmill: incremental or constant-loadexercise.11 Advantages of constant-load treadmill testing
are that tests are well accepted by patients, that this proce-
dure provides a consistent comparison with the existing
literature for more than 2 decades, and requires minimal
equipment. Criticisms of constant-load, as opposed to
graded treadmill testing, include the problem of using a
single stress level for a population with potential heteroge-
neous usual walking speed and an apparent higher variabil-
ity than incremental testing. Respective advantages and
limits of constant-load vs incremental tests have been
largely reviewed by Hiatt et al.11 A wide variety of treadmill
protocols have been used in patients with PAD for treadmill
tests, with speeds ranging from 2.5 to 4.0 km hour1 and
grades ranging from 0 to 12.5%.5,6,12-14 Whatever the
protocols, using a speed of 3.2 km/hour1 with a 10% to
12% grade are the most largely used ones.15,16
Treadmill maximal walking distance as a gold
standard. Defining a duration at which the test is stopped
is a problem specific to all constant-load treadmill tests. It is
well known that patients with claudication may remain
asymptomatic and be unlimited if the walking speed is
decreased.17 Further, all patients with claudication do not
experience walking limitation. In patients without pain at
rest, nonlimiting claudication may represent 11% of PAD
patients and 14.6% of patients with exercise-induced lower
limb symptoms.18
Various limits for treadmill test durations are reported
in the literature. Very short walking tests (3 minutes) are
likely to be sufficient to induce ischemia and allow hemo-
dynamic or metabolic investigations in PAD patients19-21
but unlikely sufficient to reach maximal walking distance in
most patients. Following the initial suggestion by Ruther-
ford,1 many authors evaluate therapies for PAD on the
subject’s ability to complete a constant-load exercise test of
5 minutes (250 meters).2 Other authors use 5- or 10-
minute tests.3,4 Lundren et al5 apparently maximized their
tests to 9 minutes (600 meters), although this was not
specified in the method of the manuscript. We previously
used a maximum duration of 20 minutes (3.2 km/hour,
10% slope, 1000 meters) as did Womack et al6 with a 0%
slope, whereas other authors maximized their test to 30
minutes (1600 meters).7 It is likely that longer durations
for the tests would lead to fatigue. Indeed, more than half
of the patients with PAD walk less than 2 miles per week.22
It is of interest to note here that fatigue was recorded as the
cause of exercise ending in less than 10% of our patients
who stopped between 250 and 1000 meters. Maximizing
the test duration to 5 minutes (250 meters) is probably
not long enough because almost half of the patients who
walked up to 250 meters had to stop within the next 250
meters. In other words, if limitation was based on the ability
to complete a treadmill test, these patients would be classi-
fied differently if only the test had been prolonged 5 more
minutes. On the contrary, with respect to the distribution
of MWDTT, it seems that tests lasting more than 15 min-
utes (750 meters) are probably of little interest. Indeed,
only 16 of 213 patients (7.5%) who walked 750 meters
stopped in the next 250 meters. Thus, 15 minutes could be
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duration of these tests.
Self-reported maximum walking distance as a gold
standard. One might argue that using self-reported max-
imal walking distance as the gold standard for assessing
functional limitations is easier than to perform a treadmill
test. A low concordance of MWDSR and MWDTT in pa-
tients with claudication as observed in our population is a
constant finding in the literature. The apparently most
intuitive reason for this discordance is that subjects may
report limitation on a treadmill whereas they do not expe-
rience exercise-related pain or limitation in daily living due
to limited ambulation.23 It is possible that walking on a
treadmill at 3.2 km/hour1 and with a 10% slope may
decrease the walking capacity as compared to usual walking,
because different exercise modalities of comparable work
load may result in differences in exercise-induced symp-
toms.24 Inversely, patients may underestimate their walk-
ing capacity and be unlimited on a treadmill while reporting
limitation by history. Despite walking capacity estimated to
be less than 250 by history, 27 patients were able to
complete the 20-minute (1000 meter) treadmill test.
Among many other possible reasons, evidence exists that
patients suffering peripheral vascular disease poorly esti-
mate their walking distance by history.25 Whatever, if
constant-load treadmill testing is used for the confirma-
tion of walking limitation (MWDSR being used as a gold-
standard), from the ROC curve analysis, we suggest that
the lower limit for test predefined duration is the one
allowing to reach 299 meters (the optimal cutoff point for
the prediction of MWDSR from MWDTT). Using our pro-
tocol, this duration is precisely 6 minutes and 10 seconds.
Then 7 minutes could be proposed as a reasonable lower
limit for the predefined duration of these tests.
Study limitations. A population bias may have oc-
curred in the present study because, as a referral center, the
patients who are referred to our laboratory may not be
representative of patients who may enter a study of arterial
claudication. Specifically our interest in buttock claudica-
tion9,26-28 results in a large number of studied patients
referred for atypical (proximal “buttock” and not distal
“calf”) symptoms. It cannot be excluded that treadmill
walking capacitymay differ between a patient with proximal
vs distal symptoms. The fact that 7.1% of our patients had
been treated or investigated for lumbar spine syndrome is
unlikely to bias the results because it is in the same range as
previous reports of an 11% prevalence of spinal stenosis in
patients with PAD.29
Furthermore, 86% of our patients were male. Although
most studies of patients with PAD include dominantly
males, this proportion is particularly high, and the explana-
tion for this is not readily apparent. Last, it is clear that our
results are of little interest (at least for the maximum
duration) for physicians who use an incremental treadmill
test and may not be transferable to other constant-load
procedures.CONCLUSION
The predefined duration of exercise at which the test
should be stopped depends on the goal of the treadmill test.
On the one hand, if MWDSR is the gold standard and one
aims at confirming a self-reported limitation by history, our
results suggest that when limitation by history is defined as
anMWDSR lower than 1000meters in patients undergoing
constant-load treadmill exercise with a protocol of 3.2
km/hour1 and 10% slope, a test duration of at least 7
minutes allows for the optimal cutoff point for MWDTT
(299 meters) to be reached. Then 7 minutes could be
proposed as a reasonable lower limit for the predefined
duration of the test. On the other hand, if MWDTT is used
as a gold standard to define exercise limitation, one should
keep in mind that the probability that the patients who
could reach a certain distance will stop in the next 5minutes
if the test is not ended, decreases almost exponentially with
time and was less than 10% after 750 meters (15 min-
utes). All patients will theoretically reach a limit (at least
due to fatigue) if time was extended indefinitely, but 15
minutes could be proposed as a reasonable upper limit for
the predefined test duration.
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